Literature DB >> 11370955

Antihypertensive therapy in diabetic hypertensive patients.

F H Messerli1, E Grossman, U Goldbourt.   

Abstract

BACKGROUND: We analyzed the available data to assess the benefits of antihypertensive therapy in hypertensive patients with diabetes mellitus. PROCEDURE: A MEDLINE search of English-language articles published until June 1999 was undertaken using the terms diabetes mellitus, hypertension or blood pressure (BP), and therapy. Included were only prospective randomized studies of more than 12 months' duration that evaluated the effect of drug treatment on morbidity and mortality in diabetic hypertensive patients.
RESULTS: The coexistence of diabetes mellitus doubled the risk of cardiovascular events, cardiovascular mortality, and total mortality in hypertensive patients (approximate relative risk of 1.73 to 2.77 for cardiovascular events, 2.25 to 3.66 for cardiovascular mortality, and 1.73 to 2.18 for total mortality). Intensive BP control to levels lower than 130/85 mm Hg was beneficial in diabetic hypertensive patients. All four drug classes--diuretics, beta-blockers, angiotensin converting enzyme inhibitors, and calcium antagonists--were effective in reducing cardiovascular events in diabetic hypertensive patients. In elderly diabetic patients with isolated systolic hypertension, calcium antagonists reduced the rate of cardiac end points by 63%, stroke by 73%, and total mortality by 55%. In more than 60% of diabetic hypertensive patients, combination therapy was required to control BP.
CONCLUSIONS: Intensive control of BP reduced cardiovascular morbidity and mortality in diabetic patients regardless of whether low-dose diuretics, beta-blockers, angiotensin converting enzyme inhibitors, or calcium antagonists were used as a first-line treatment. Combination of more than one drug is frequently required to control BP and may be more beneficial than monotherapy.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11370955     DOI: 10.1016/s0895-7061(01)01314-0

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  8 in total

Review 1.  Treatment of coexisting diabetes and hypertension.

Authors:  N M Kaplan
Journal:  Curr Cardiol Rep       Date:  2001-11       Impact factor: 2.931

Review 2.  Earlier management of subjects who are prone to hypertension and diabetes mellitus.

Authors:  Hiromi Rakugi; Toshio Ogihara
Journal:  Curr Diab Rep       Date:  2004-04       Impact factor: 4.810

3.  Issue editor.

Authors:  A Burshell
Journal:  Ochsner J       Date:  2001-07

4.  Pharmacogenetic association of hypertension candidate genes with fasting glucose in the GenHAT Study.

Authors:  Marguerite R Irvin; Amy I Lynch; Edmond K Kabagambe; Hemant K Tiwari; Joshua I Barzilay; John H Eckfeldt; Eric Boerwinkle; Barry R Davis; Charles E Ford; Donna K Arnett
Journal:  J Hypertens       Date:  2010-10       Impact factor: 4.844

5.  Effect of benazepril amlodipine combination on fibrinolysis in hypertensive diabetic patients.

Authors:  Roberto Fogari; Paola Preti; Pierangelo Lazzari; Luca Corradi; Annalisa Zoppi; Elena Fogari; Amedeo Mugellini
Journal:  Eur J Clin Pharmacol       Date:  2003-06-27       Impact factor: 2.953

6.  Effect of 8-Week Combination Therapy with an Extended-Release α1-Blocker (Bunazosin or Doxazosin) in Inadequate Responders to an Angiotensin II Antagonist (Valsartan) in Patients with Stage 1 or 2 Essential Hypertension.

Authors:  Shao-Chi Yang; Wei-I Tsai; Chiau-Suong Liau; Tzung-Dau Wang
Journal:  Acta Cardiol Sin       Date:  2013-01       Impact factor: 2.672

7.  Beneficial effect of combination therapy with antihypertensive drugs in patients with hypertension.

Authors:  Chihiro Shikata; Tetsuaki Sekikawa; Nobuaki Kimura; Akira Kojima; Shingo Seki; Hisayoshi Oka; Akihiro Nishiyama; Nobuakira Takeda
Journal:  Exp Clin Cardiol       Date:  2007

8.  Differential associations of central and brachial blood pressure with carotid atherosclerosis and microvascular complications in patients with type 2 diabetes.

Authors:  Chan-Hee Jung; Sang-Hee Jung; Kyu-Jin Kim; Bo-Yeon Kim; Chul-Hee Kim; Sung-Koo Kang; Ji-Oh Mok
Journal:  BMC Cardiovasc Disord       Date:  2014-02-20       Impact factor: 2.298

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.